Pfizer’s alopecia treatment receives Breakthrough Therapy designation

By Marcus Lawrence
In a press release on 5 September, Pfizer announced that its in-development investigational oral Janus kinase (JAK3) inhibitor PF-06651600 has been gran...

In a press release on 5 September, Pfizer announced that its in-development investigational oral Janus kinase (JAK3) inhibitor PF-06651600 has been granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA).

It is hoped that the inhibitor will aid in the treatment of alopecia areata, an autoimmune disease that causes hair loss around the body.

The designation was supported by success in a Phase 2 study, the positive results of which will be revealed at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris on 15 September.

Pfizer’s press release noted that there are as yet “no FDA-approved treatments for alopecia areata, a condition which impacts millions of people worldwide and is often associated with profound psychological consequences”.

SEE ALSO:

Michael Corbo, Chief Development Officer of Inflammation and Immunology for Pfizer Global Product Development, said:

“We are encouraged by this Breakthrough Therapy designation as it underscores the potential of our JAK3 inhibitor to address a critical unmet need”.

He added, “We are continuing to work closely with the FDA on the development process with the goal of bringing this potential new treatment to patients living with alopecia areata as soon as possible”.

“If a drug is designated as a Breakthrough Therapy, the FDA will expedite the development and review of such drug”, the press release continued.

In addition, Pfizer is discussing the clinical development programme for the JAK3 inhibitor with the European Medicines Agency.

Share

Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare

Hospitals